29 July 2026 को ICMR (Indian Council of Medical Research) — National Institute of Cancer Prevention and Research (NICPR) ने SHetA2 — एक oral small-molecule therapy — को HPV (Human Papillomavirus) related cervical disease के treatment में promising बताया। SHetA2 एक synthetic retinoid-related compound है जो HPV-infected cells में apoptosis (programmed cell death) induce करता है। Cervical Cancer India में महिलाओं का दूसरा सबसे common cancer है — annually 1.23 लाख नए cases और 77,000+ deaths। HPV vaccine (Gardasil, Cervarix) primary prevention है पर SHetA2 treatment option के रूप में उभर रहा है।
विज्ञानहिंदी
SHetA2 — HPV-Related Cervical Disease के लिए Oral Small-Molecule Therapy; ICMR-NICPR; India में Cervical Cancer की बड़ी समस्या
मुख्य बिंदु
- 29 July 2026 को ICMR (Indian Council of Medical Research) — National Institute of Cancer Prevention and Research (NICPR) ने SHetA2 — एक oral small-molecule therapy — को HPV (Human Papillomavirus) related cervical disease के treatment में promising बताया
- SHetA2 एक synthetic retinoid-related compound है जो HPV-infected cells में apoptosis (programmed cell death) induce करता है
- Cervical Cancer India में महिलाओं का दूसरा सबसे common cancer है — annually 1.23 लाख नए cases और 77,000+ deaths
- HPV vaccine (Gardasil, Cervarix) primary prevention है पर SHetA2 treatment option के रूप में उभर रहा है
📋
📎 मूल स्रोत पढ़ें ↗परीक्षा नोट
• SHetA2: oral small-molecule therapy for HPV-related cervical disease; ICMR-NICPR (July 29, 2026) • SHetA2: synthetic retinoid-related compound; induces apoptosis in HPV-infected cells • Cervical cancer: India's 2nd most common female cancer; 1.23 lakh new cases/year; 77,000+ deaths • HPV vaccines: Gardasil (Merck) and Cervarix (GSK); India's domestic HPV vaccine: Cervavac (Serum Institute)
